Tiziana Life Sciences (TILS)

 

TILS Share PerformanceMore

52 week high240.00 25/04/17
52 week low102.05 08/06/17
52 week change -48.50 (-25.46%)
4 week volume110,618 25/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tiziana says development of oral formulation of foralumab to be used in clinical studies

Tiziana Life Sciences announced the development of a novel, proprietary, oral formulation of foralumab, a fully human ...

A Proprietary Oral Formulation of Foralumab

RNS Number: 8848P Tiziana Life Sciences PLC 06 September 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH Successfully developed a novel formulation enabling oral immunotherapy with foraluma...

Grant of options - Director's dealing

RNS Number: 4431P Tiziana Life Sciences PLC 31 August 2017 Tiziana Life Sciences PLC ("Tiziana" or the "Company") Grant of options - Director's dealing London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that ...

Tiziana converts loan notes to shares

Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) h...

Conversion of outstanding loan notes

RNS Number: 0883O Tiziana Life Sciences PLC 16 August 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Conversion of outstanding loan notes, amendment of warrant terms and issue of equity London, August 16, 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and aut...

Publication of Research Article on Foralumab

RNS Number: 3714M Tiziana Life Sciences PLC 28 July 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases Foralumab (NI-0401) is a unique oral therapy that stimulates the gut immune system and ...

Tiziana enrols first patient in Phase IIa clinical trial

Tiziana Life Sciences announced the enrolment of the first patient in its Phase IIa clinical trial with milciclib, a novel inhib...

Initiation of a Phase IIa Clinical Trial

RNS Number: 4306L Tiziana Life Sciences PLC 19 July 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma Milciclib, a novel inhibitor of pan-CDKs, has shown clinical responses in refractory cancer patients London, 19 July, 2017 -...

Fundamental DataMore

EPS-7.7
Dividend yield0 %

Equity Research (TILS)

equity development
Tiziana Life Sciences PLC
26/01/2015
TILS has just announced an exclusive license with Nerviano Medical Sciences (NMS) for its Phase 2 anti-cancer drug candidate, milciclib. It helps block the rampant cell division associated with...
equity development
Tiziana Life Sciences PLC
12/01/2015
Tiziana (TILS) and Novimmune S.A., a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer, have announced...
equity development
Tiziana Life Sciences PLC
30/09/2014
Tiziana Life Sciences (TILS) has identified a potential 'master regulator' for metastatic breast cancer (mBC). 'Bcl-3 inhibition' would be a novel strategy for treatment,...

Latest discussion posts More

  • Top up

    Bad news this am but couldn't resist a 500 top up at 115.06.
    8-Jun-2017
    osammyboy
  • Fundraise

    Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both ...
    8-Jun-2016
    Simbr
  • no buying

    With sp @110 and bid @ 115 I tried buying 2500 online at Barclays. Quoted 187.4 Obviously buying is being discouraged for whatever reason
    28-Apr-2016
    osammyboy

Users' HoldingsMore

Users who hold Tiziana Life Sciences also hold..
LENOVO63%
LLOYDS GRP.29%
ROYAL BANK SCOT20%
TAYLOR WIMPEY15%
BARCLAYS13%

Codes & Symbols

ISINGB00BKWNZY55
SymbolsTILS, LSE:TILS, TILS.L, TILS:LN, LON:TILS, XLON:TILS